<text id="http://medicine.ucsf.edu/housestaff/handbook/HospH2002_C7.htm" title="HEMATOLOGY / ONCOLOGY" encoding="windows-1252">
<html>

<head>
<meta name=Generator content="Microsoft Office HTML Filter 2.0">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Originator content="Microsoft Word 9">
<title>HEMATOLOGY / ONCOLOGY</title>
<style>
<!--
 
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
h1
	{margin:0in;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman";
	color:blue;}
h2
	{margin:0in;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:normal;
	font-style:italic;}
h3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:normal;
	font-style:italic;}
h4
	{margin:0in;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;}
h5
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:Helvetica;
	color:black;
	text-decoration:underline;}
h6
	{margin:0in;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	text-decoration:underline;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:13.7pt;
	margin-bottom:.0001pt;
	text-indent:-13.7pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:bold;
	text-decoration:underline;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-indent:-.25in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:bold;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";}
span.MsoFootnoteReference
	{vertical-align:super;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman";
	color:black;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman";
	color:black;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman";
	color:black;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	background:navy;
	font-size:10.0pt;
	font-family:Tahoma;}
span.msodel0
	{
	color:red;
	display:none;
	text-decoration:line-through;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
</head>

<body lang=EN-US link=blue vlink=purple>

<div class=Section1>

<p class=MsoNormal><b><i><span style='font-size:22.0pt;font-family:"Garamond Book";
color:#3366FF'>Hematology/Oncology</span></i></b></p>

<p class=MsoNormal><span style='font-size:9.0pt;color:#3366FF'>Garth A.
Beinart, M.D.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;color:#3366FF'>Sumitra Chari,
M.D.</span></p>

<p class=MsoTitle align=left style='text-align:left'><span style='font-size:
9.0pt;color:#3366FF;font-weight:normal'>Willis H. Navarro, M.D.</span></p>

<p class=MsoTitle><i><span style='font-family:"Garamond Book";font-weight:normal'>&nbsp;</span></i></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_ANEMIA_OVERVIEW">Anemia overview</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_MICROCYTIC_ANEMIA_(MCV">Microcytic anemia</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_NORMOCYTIC_ANEMIA_(MCV">Normocytic anemia</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_MACROCYTIC_ANEMIA_(MCV">Macrocytic anemia</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_DEEP_VEIN_THROMBOSIS">Deep vein thrombosis</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a href="#_HEPARIN">Heparin</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a href="#_WARFARIN">Warfarin</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_OUTPATIENT_THERAPY_FOR">Outpatient therapy for venous thromboembolism</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_SUPRATHERAPEUTIC_PT/PTT">Supratherapeutic PT/PTT</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_UREMIC_BLEEDING">Uremic bleeding</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_BLOOD_PRODUCTS_–">Blood products – components</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_BLOOD_PRODUCTS_–_1">Blood products – complications</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_NEUTROPENIC_FEVER:_ABSOLUTE">Neutropenic fever</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_SICKLE_CELL_PAIN">Sickle cell pain crisis</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_THROMBOCYTOPENIA">Thrombocytopenia</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_HEPARIN-INDUCED_THROMBOCYTOPENIA_(HIT)">Heparin-induced
thrombocytopenia</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_BONE_MARROW_TRANSPLANT">Bone marrow transplant—potential complications</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a href="#_BMT_–_ACUTE">BMT—acute
graft vs. host disease staging and grading</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_ONCOLOGIC_EMERGENCIES">Oncologic emergencies</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_PAIN_MANAGEMENT">Pain management</a></span></p>

<p class=MsoSubtitle><span style='font-weight:normal'><a
href="#_COMMON_CHEMOTHERAPY_SIDE">Common chemotherapy side effects</a></span></p>

<p class=MsoSubtitle>&nbsp;</p>

<p class=MsoSubtitle>&nbsp;</p>

<h1><a name="_ANEMIA_OVERVIEW"></a>ANEMIA OVERVIEW</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Symptoms</span></b><span style='font-size:11.0pt;color:black'> of
anemia include fatigue, dyspnea on exertion, and even angina.&nbsp; <b>Physical
exam</b> findings include pallor, tachycardia, and jaundice.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>2.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>To generate a <b>differential diagnosis</b>
anemia, first categorize the type of anemia (microcytic, normocytic,
macrocytic) by MCV and furthermore with the ferritin and reticulocyte
count.&nbsp; Then, exam the peripheral smear: findings on the smear will narrow
your differential, suggest additional medical problems the patient may have (<i>i.e.</i>
target cells and liver disease, spur cells and uremia with uremic platelet
dysfunction), and may reveal diagnoses such as microangiopathic hemolytic
anemia (MAHA) in a timely fashion.&nbsp; Finally, order additional tests to
confirm your diagnosis and remember to get your tests before transfusing the
patient.</span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Factoids:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Hospitalized patients will drop their
hematocrit 1% per day from blood draws.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Epogen® causes hypertension if the
hematocrit is raised &gt; 35% in ESRD and does not work in the setting of iron
deficiency.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Follow the hemoglobin and not the
hematocrit. The hematocrit is calculated from two measured values and has a </span><span
style='font-size:11.0pt;font-family:Symbol;color:black'>±</span><span
style='font-size:11.0pt;color:black'> 3 point range for error.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:12.0pt;font-family:Arial;
color:black'>&nbsp;</span></b></p>

<h1><a name="_MICROCYTIC_ANEMIA_(MCV"></a>MICROCYTIC ANEMIA (MCV &lt; 80)</h1>

<p class=MsoNormal><b><span style='font-size:12.0pt;font-family:Arial;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Work-up: </span></b><span style='font-size:11.0pt;color:black'>order
iron, ferritin, transferrin, and if possible a red cell distribution width
(RDW).</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Iron deficiency:</span></b><span style='font-size:11.0pt;
color:black'> On physical exam, look for koilonychia, atrophic tongue.&nbsp;
Iron deficiency usually does not cause a microcytic anemia until the hematocrit
drops below 30%.&nbsp; Ferritin is useful for diagnosing iron deficiency. The
likelihood ratios are as follows: for a ferritin &lt;15 the LR=50 in favor of
iron deficiency anemia; for a ferritin &lt;25 the LR=10, specificity of 98%;
for a ferritin &gt;100 the LR=0.1. Since ferritin is an acute phase reactant,
some say it should not be used in the setting of inflammation; others say that
in chronic inflammation a ferritin &lt; 50 is highly suggestive of iron
deficiency.&nbsp; Iron is low and transferrin or TIBC (total iron binding
capacity) is high, which makes the transferrin saturation (iron divided by
transferrin) low: a saturation &lt;10% has a specificity of 88%. The RDW
(reflecting anisocytosis) is high. Once you’ve made the diagnosis, rule out GI
bleeding: around 60% of patients will have GI lesions. Order stool guiaics, a
colonoscopy, and possibly an EGD.&nbsp; With treatment, the hematocrit should
be normal in 2 months; continue iron treatment 4-6 months to replete stores.
Common side effect of oral iron is constipation.&nbsp; IV iron available if
patient refractory to PO, but has increased risk of anaphylaxis. Each PRBC
transfused contains 200 mg elemental iron.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Sideroblastic anemia:</span></b><span style='font-size:11.0pt;
color:black'> hereditary cases are usually microcytic while acquired
sideroblastic anemia may be normocytic. Acquired causes include lead, INH,
EtOH, B<sub>6</sub> deficiency. Basophilic stippling and dimorphic RBC
morphology is seen on peripheral blood smear.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Thalassemia:</span></b><span style='font-size:11.0pt;color:black'>
The Mentzer index may be helpful: (MCV/RBC count) &lt; 13 favors thalassemia
over iron deficiency.&nbsp; This test has a high sensitivity but low
specificity.&nbsp; Basically in iron deficiency, the marrow can’t produce RBCs
and they’re small so the RBC count will be low along with the MCV.&nbsp; In
thalassemia, RBC production is preserved, though the cells are small and
fragile.&nbsp; So the RBC count is normal with a low MCV.&nbsp; This concept
may be more helpful than remembering the Mentzer index.&nbsp; The RDW in
thalassemia, unlike iron deficiency, is normal and may be a more accurate
discriminant function in differentiating between the two.&nbsp; Make the
diagnosis of beta-thalassemia with hemoglobin electrophoresis.
Alpha-thalassemia will not show up on electrophoresis: it is diagnosed by
molecular diagnostic techniques. Order an “A-thal” on the lab slip. Think of <b>A</b>lpha
thalassemia in <b>A</b>sians.&nbsp; Beta thal in Meditteraneans.&nbsp;&nbsp;
Differential diagnosis for target cells on smear: beta thalassemia, hemoglobin
C disease, liver disease, beta-lipoproteinemia.&nbsp; In general you should not
see targets in sickle cell unless they are sickle-thalassemia or sickle-C.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>5.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Anemia of chronic disease:</span></b><span style='font-size:11.0pt;
color:black'> Chronic inflammatory diseases, that is, such as cancer and
collagen-vascular diseases. Transferrin is decreased, saturation increased,
iron low, ferritin normally increased (non specific for chronic disease). The
MCV rarely falls below 78, though the patient can become microcytic because
they are functionally deficient of iron.</span></p>

<h1><span style='font-weight:normal'>&nbsp;</span></h1>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial'>Guyatt
GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of
iron-deficiency anemia: an overview.&nbsp; J Gen Intern Med. 1992
Mar-Apr;7(2):145-53.</span></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<h1><a name="_NORMOCYTIC_ANEMIA_(MCV"></a>NORMOCYTIC ANEMIA (MCV 80-100)</h1>

<h1>&nbsp;</h1>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Reticulocytes:</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>First check a reticulocyte count.&nbsp; Your goal
     is to come up with a <i>reticulocyte index </i>(RI).</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>If your lab gives you an <i>absolute</i>
     reticulocyte count, make into a <i>percent</i> reticulocyte count by
     dividing by the RBC count.&nbsp; <i>Make sure to convert your units!</i></span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Now correct the reticulocyte count for the
     patient’s hematocrit (HCT).&nbsp; Corrected reticulocyte count = %
     reticulocytes x (actual hematocrit </span><span style='font-size:11.0pt;
     font-family:Symbol'>¸</span><span style='font-size:11.0pt'> ideal
     hematocrit).</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Now correct for early release of reticulocytes by
     dividing by (1 + 0.5<i>x</i>) where <i>x</i> is 1 for every drop of 10% in
     the hematocrit.&nbsp; For example, divide by 1.5 for HCT=35% and divide by
     2 for HCT=25%.</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>You now have the reticulocyte index (RI).&nbsp;
     If the RI &lt; 2 for HCT 10-35%, or &lt; 3 for HCT &lt; 10%, your patient
     has a hypoproliferative anemia.</span></li>
</ul>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Decreased reticulocyte count:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Primary bone marrow failure:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Aplastic anemia/red cell aplasia</span></i><span
style='font-size:11.0pt;color:black'>: diagnosed by bone marrow biopsy.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Myelophthisis</span></i><span
style='font-size:11.0pt;color:black'>: (replacement of the bone marrow) tear
drops on smear</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Myelodysplastic syndrome</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Secondary bone marrow failure:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Anemia of chronic disease</span></i><span
style='font-size:11.0pt;color:black'>: Normal or increased platelets and WBCs
support this is the diagnosis.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Iron, B12, folate deficiency (nutritional
deficiency)</span></i></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Chronic kidney disease</span></i><span
style='font-size:11.0pt;color:black'>: use erythropoeitin when the creatinine
clearance drops below 30 ml/min.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Hypersplenism</span></i><span
style='font-size:11.0pt;color:black'>: usually anemia is concomitant with mild
pancytopenia.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Hypothyroidism</span></i><span
style='font-size:11.0pt;color:black'>: especially in the elderly</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Multiple myeloma</span></i><span
style='font-size:11.0pt;color:black'>: check SPEP, UPEP</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>HIV/AIDS</span></i></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Mixed: e.g.</span></i><span
style='font-size:11.0pt;color:black'> an alcoholic with megaloblastic anemia
from folate deficiency, and iron deficiency from GI bleeding. The MCV is
normal, but the RDW is increased reflecting anisocytosis (cells of varying
sizes).</span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Increased reticulocyte count</span></b><span style='font-size:
11.0pt;color:black'>: check smear for schistocytes (intravascular hemolysis)
and/or spherocytes (extravascular hemolysis).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Acute blood loss</span></i><span
style='font-size:11.0pt;color:black'>: If you can’t find a source, don’t forget
to rule out occult retroperitoneal bleed.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Correction</span></i><span
style='font-size:11.0pt;color:black'>: of a production deficit. Peak MCV at
7-10 days.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Hemolysis</span></i><span
style='font-size:11.0pt;color:black'>: see below.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>5.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Hemolysis:</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Classification is based on:</span></li>
</ul>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt'>-</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt;color:black'>Site of hemolysis
(intravascular vs. extravascular) <i>or</i></span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt'>-</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt;color:black'>Intrinsic (RBC defect) vs. an
acquired extrinsic mechanism (where transfused cells will have a shortened life
span).</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt'>-</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt;color:black'>Send LDH, total and direct bilirubin,
and possibly haptoglobin (level &lt; 25 is 96% specific for hemolysis).&nbsp; A
normal LDH and haptoglobin &gt; 25 helped rule out hemolysis in one small
study.&nbsp; Haptoglobin overall is not very useful as it takes one week to
return, is an acute phase reactant, and is <i>very</i> sensitive (leading to
decreased specificity).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Intravascular causes:&nbsp; red cell
     fragmentation syndromes, PNH, immediate transfusion reactions. Look for
     schistocytes and urine hemoglobin/hemosiderin/heme+ (sensitive).</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Extravascular causes: RBCs destroyed by the
     reticuloendothelial system.</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Extrinsic causes:</span></li>
</ul>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt'>-</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><i><span style='font-size:11.0pt;color:black'>Hypersplenism</span></i></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Antibody-mediated</span></i><span
style='font-size:11.0pt;color:black'>: warm (IgG) vs. cold (Ig<b>M</b>) think <b>M</b>ono,
<b>M</b>ycoplasma;check Coomb’s. Spherocytes are on the smear. Drugs are a big
offender as well.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Trauma/ Red Cell fragmentation</span></i><span
style='font-size:11.0pt;color:black'>: heart valve, hemodialysis, malignant
HTN, vasculitis, HELLP, cardiopulmonary bypass, TTP/HUS, DIC.&nbsp; Look for
schistocytes and helmet cells (even 1-2 per HPF), and spherocytes. Remember:
DIC increases INR and PTT, HUS and TTP do not.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Infection/toxin: </span></i><span
style='font-size:11.0pt;color:black'>malaria, babesiosis, clostridia,
brown-recluse, copper (Wilson’s disease).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Intrinsic defects: <i>all are hereditary
except PNH.</i></span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Membrane:</span></i><span
style='font-size:11.0pt;color:black'> Hereditary spherocytosis, hereditary
elliptocytosis.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Enzyme:&nbsp; e.g.</span></i><span
style='font-size:11.0pt;color:black'> G6PD deficiency: normal smear and
Coomb’s. Check G6PD levels, which may be normal after an acute hemolytic
episode or post transfusion. Consider this in HIV patients, particularly
African Americans, taking PCP prophylaxis. Although this is X-linked recessive,
it may still occur in females due to lyonization.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Hemoglobinopathy:</span></i><span
style='font-size:11.0pt;color:black'> sickle cell, thalassemias, Hgb C, Hgb E.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>PNH</span></i><span style='font-size:11.0pt;
color:black'>: complement-mediated lysis. Consider with pancytopenia, unexplained
thrombosis (especially intra-abdominal) and an elevated reticulocyte count and
LDH. A rare diagnosis.</span></p>

<p class=MsoNormal><b><span style='font-size:12.0pt;font-family:Arial;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Marchand A, Galen RS, Van Lente F.&nbsp;&nbsp; The predictive
value of serum haptoglobin in hemolytic disease.</span></i></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>JAMA. 1980 May 16;243(19):1909-11.</span></i><b><span
style='font-size:12.0pt;font-family:Arial;color:black'><br clear=all
style='page-break-before:always'>
</span></b></p>

<p class=MsoNormal><b><span style='font-size:12.0pt;font-family:Arial;
color:black'>&nbsp;</span></b></p>

<h1><a name="_MACROCYTIC_ANEMIA_(MCV"></a>MACROCYTIC ANEMIA (MCV &gt; 100)</h1>

<h1>&nbsp;</h1>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Megaloblastic</span></b><span style='font-size:11.0pt;color:black'>:
hypersegmented neutrophils (&gt; 5% of neutrophils with 5 lobes or &gt; 1% with
6 lobes) are seen on the smear. An MCV &gt; 120 is almost pathognomonic for
megaloblastic anemia. Ovalocytes may be seen, but are nonspecific. On physical
exam, look for atrophic tongue.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>B12 deficiency</span></i><span
style='font-size:11.0pt;color:black'>: diagnose with serum B12. This value may
be falsely decreased secondary to folate deficiency or type 1 cryoglobulinemia
(<i>e.g.</i> multiple myeloma, Waldenstrom’s macroglobulinemia). Look for
subacute combined degeneration.&nbsp; Can send homocysteine and methylmalonic
acid.&nbsp; Schilling test to look at source of deficiency. May have
pancytopenia.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Folate deficiency</span></i><span
style='font-size:11.0pt;color:black'>: diagnose with RBC-Folate level.&nbsp;
(Serum folate fluctuates and is a poor proxy for folate stores).&nbsp; May be
falsely low secondary to B12 deficiency.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Drug-induced</span></i><span
style='font-size:11.0pt;color:black'>: chemo, methotrexate (MTX), hydroxyurea,
azathioprine, etc.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Note: repletion of vitamin B12 should
always accompany folate and iron therapy until you are sure the patient does
not have multiple deficiencies, in order to avoid aplastic-type crisis and/or
high output CHF.&nbsp; In addition, folate may partially correct the
megaloblastic anemia of B12 deficiency while the neurologic symptoms progress.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Non-megaloblastic</span></b><span style='font-size:11.0pt;
color:black'>: MCV &lt; 110 in most cases.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Alcoholism</span></i><span style='font-size:11.0pt;
color:black'>: most common cause of macrocytic anemia.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Liver disease</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Hypothyroidism</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Reticulocytosis</span></i><span style='font-size:11.0pt;
color:black'>: although the reticulocyte MCV is 160 microns, reticulocytosis rarely
causes an MCV above 110.&nbsp; Polychromasia is seen on smear.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Spurious</span></i><span style='font-size:11.0pt;
color:black'>: hyperglycemia and hypernatremia, secondary to osmotic swelling.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Aplastic</span></i><span style='font-size:11.0pt;
color:black'> <i>anemia</i></span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Myelodysplastic syndromes</span></i><span style='font-size:
11.0pt;color:black'>: giant platelets, hypogranulated neutrophils, bi-lobed
neutrophils.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span style='font-size:
11.0pt;color:black'>Drugs:</span></i><span style='font-size:11.0pt;color:black'>
anticonvulsants, AZT.</span></p>

<p class=MsoNormal style='margin-left:.25in'><b><span style='font-size:11.0pt;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Hoffbrand V, Provan D.&nbsp;&nbsp; ABC of clinical haematology.
Macrocytic anaemias.&nbsp; BMJ. 1997 Feb 8;314(7078):430-3.</span></i></p>

<h6><span style='font-weight:normal'>&nbsp;</span></h6>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_DEEP_VEIN_THROMBOSIS"></a>DEEP VEIN THROMBOSIS</h1>

<p class=MsoBodyText><span style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>1.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>See also <i><a href="HospH2002_C4.htm#PE">Pulmonary:
Pulmonary embolism</a>.</i></span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>2.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>Over 9 in 10 pulmonary emboli originate
from DVTs, and the treatment of PE and DVT are usually identical.</span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>3.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>DVTs are associated with calf pain and
tenderness. Homan’s sign—pain when dorsiflexing the foot with the knee
extended—is neither sensitive nor specific and should be abandoned.</span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>4.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>DVT prophylaxis should be addressed in
all inpatients. Encourage early ambulation and order physical therapy when
indicated. Obtain prophylaxis with sequential compression devices, low dose ultrafractionated
heparin, or low molecular weight heparin (<i>e.g. </i>enoxaparin).&nbsp; See
also <i><a href="HospH2002_C14.htm#_DVT/PE_PROPHYLAXIS">Medical Consultation:
DVT/PE prophylaxis</a>.</i></span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>5.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Simple clinical model to diagnose DVT:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Give the patient one (1) point for each of the following (if they
are present): active cancer, immobilization, bedridden &gt; than 3 days due to
surgery, localized tenderness, entire leg swelling, asymmetric &gt; 3 cm calf
swelling,&nbsp; pitting edema, or collateral superficial veins (nonvaricose).</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Is there an alternative diagnosis that is as
     likely or more likely than DVT?&nbsp; If yes, subtract 2 points.</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Score &gt; 3: <i>high probability of DVT,
     prevalence of DVT 75%</i>.</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Score 1-2: <i>moderate probability of DVT,
     prevalence of DVT 17%</i>.</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>Score 0: <i>low probability of DVT, prevalence of
     3%</i>.</span></li>
</ul>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>6.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Work-up of suspected DVT:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>D-dimers</span></i><span style='font-size:
11.0pt;color:black'>: very useful if your local hospital has the ELISA test
which is very sensitive (good for ruling out DVT).&nbsp; Some labs use the
latex agglutination test, which is only 85-90% sensitive. Thus, in a patient
with a non-diagnostic V/Q scan (for PE) or Doppler ultrasound (for DVT), a
negative D-dimer (ELISA method) means it is probably safe not to anticoagulate
if your clinical suspicion is low or moderate.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>Doppler ultrasound</span></i><span
style='font-size:11.0pt;color:black'>: This test is better at detecting DVTs above
the knee (which, in fact, are the clinically significant ones as clots below
the knee rarely cause pulmonary embolism).&nbsp; Ultrasound is 50% sensitive in
an asymptomatic individual, and therefore cannot be used to rule out PE.
Ultrasound is also less sensitive than venogram for calf DVT.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>7.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Hypercoagulability work-up:</span></b></p>

<ol style='margin-top:0in' start=1 type=1>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>After the first event, the hypercoaguable work-up
     will lead to an etiology in only 30% of patients; after the second DVT
     only 50% will eventually have an etiology determined.&nbsp; Moreover, only
     10-20% of people with an idiopathic DVT will ever have another event.</span></li>
</ol>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>It is not necessary to begin the work up
of anticoagulation at the time of the clot: the results won’t change your
management and will take a while to come back anyway; therefore, consider an
outpatient work-up.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Guidelines for hypercoagulability work-up:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Draw an extra blue top tube before
starting heparin or warfarin if you suspect a hypercoaguable state: heparin
will interfere with assays for antithrombin III and the lupus anticoagulant.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Protein C, S, anticardiolipin antibodies,
homocysteine, prothrombin 20210A, Factor V Leiden, and MTHFR mutations (leading
to hyperhomocysteinemia) can be sent when patients are taking heparin.&nbsp; Note
that Proteins C and S are vitamin K dependent factors and will be lowered by
warfarin therapy.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>AT III, Protein C, and Protein S may be
transiently depressed during the acute event, and only persistent lupus
anticoagulants are associated with hypercoagulability. Therefore, repeat
abnormal tests later to make an accurate diagnosis.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Note that there is not a consensus that
all patients with unprovoked DVT/PE should have a hypercoagulability
work-up.&nbsp; The most common defects are not associated with recurrent
disease, and the ones that are, are uncommon.&nbsp; A targeted work-up is
likely a more reasonable approach (<i>e.g.</i> send antiphospholipid antibody
as persistent lupus anticoagulant is associated with venous/arterial recurrence
and may require a higher INR goal for warfarin therapy).</span></p>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>8.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Treatment</span></b><span
style='font-size:11.0pt'>: typically involves heparin (or enoxaparin) and
warfarin.&nbsp; Some advocate giving patients heparin for 5 days, even if their
INR becomes therapeutic in less than 5 days. Patients should be therapeutically
anticoagulated as soon as possible (within 24 hours). Thus, it is better to
overshoot and risk bleeding than to undershoot and risk further
embolic/thrombotic events.&nbsp; See <i><a href="#_HEPARIN">Hematology/Oncology:
Heparin</a> </i>and <i><a href="#_WARFARIN">Hematology/Oncology: Warfarin</a></i>
(below).</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i><span
style='font-size:9.0pt;font-family:Arial;color:black'>Anand SS, Wells PS, et
al.&nbsp; Does this patient have deep vein thrombosis? JAMA. 1998 Apr
8;279(14):1094-9.</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><i><span
style='font-size:9.0pt;font-family:Arial;color:black'>Seligsohn U, Lubetsky A.
Genetic susceptibility to venous thrombosis. N Engl J Med. 2001 Apr
19;344(16):1222-31</span></i></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Hyers TM, Agnelli G, et al.&nbsp; Antithrombotic therapy for
venous thromboembolic disease.&nbsp; Chest. 2001 Jan;119(1 Suppl):176S-193S..</span></i></p>

<p class=MsoHeading9><span style='font-weight:normal'>&nbsp;</span></p>

<p class=MsoHeading9><span style='font-weight:normal'>&nbsp;</span></p>

<h1><a name="_HEPARIN"></a>HEPARIN</h1>

<p class=MsoNormal>&nbsp;</p>

<h3><span style='font-size:11.0pt;font-style:normal'>1.</span><span
style='font-size:7.0pt;font-style:normal'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span
style='font-size:11.0pt;font-style:normal'>Risk factors for bleeding while on
heparin:</span></b></h3>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Surgery, trauma, or stroke within the
previous 14 days.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>History of peptic ulcer disease, GI
bleeding or GU bleeding.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Platelets &lt; 150K.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Age &gt; 70 years.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Hepatic failure, uremia, bleeding
diathesis, brain metastases.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>When to use low molecular weight heparin</span></b><span
style='font-size:11.0pt;color:black'> (enoxaparin): LMWH eliminates the need to
monitor PTT and adjust dosages. You may send selected patients home with
enoxaparin and warfarin, rather than keeping them in-house on heparin for 5
days or until they are therapeutic on warfarin (see <i><a
href="#_OUTPATIENT_THERAPY_FOR_1">Hematology/Oncology: Outpatient therapy for
venous thromboembolism</a></i>).&nbsp; Moreover, LMWH is associated with a
lower incidence of heparin-associated thrombocytopenia.&nbsp; Regular,
ultrafractionated heparin is preferable when:</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal><span
     style='font-size:11.0pt'>Patients require prolonged hospitalization anyway
     (cost savings over enoxaparin) <i>or</i></span></li>
 <li class=MsoNormal><span
     style='font-size:11.0pt'>Rapid reversal of anticoagulation might be
     necessary (<i>e.g.</i> possible surgery).</span></li>
</ul>

<p class=MsoNormal style='margin-left:.5in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Consider a hematology consult before using LMWH in the following
situations:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Weight &gt; 150 kg.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Creatinine &gt; 2, or creatinine clearance
&lt; 30 ml/min.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Pregnancy.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>For heparin sliding scale, see <i><a
href="HospH2002_AppD.htm#_HEPARIN">Sliding Scales: Heparin</a></i>.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Hirsh J, Warkentin TE, et al.&nbsp; Heparin and
low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing,
monitoring, efficacy, and safety.&nbsp; Chest. 2001 Jan;119(1 Suppl):64S-94S.</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><b><span
style='font-size:12.0pt;font-family:Arial;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><b><span
style='font-size:12.0pt;font-family:Arial;color:black'>&nbsp;</span></b></p>

<h1><a name="_WARFARIN"></a>WARFARIN</h1>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>1.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>Give the warfarin on day one of heparin
or enoxaparin if long-term anticoagulation is desired.&nbsp; Usually 5.0-7.5 mg
PO at night (to ensure absorption on an empty stomach) on Day 1, then 2.5-7.5
mg PO QHS (most often 5 mg). Increase in the INR of &gt; 0.3-0.4 units per day
should result in a dose reduction (otherwise an INR overshoot is likely).</span></p>

<p class=MsoBodyText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Goal for INR:</span></b></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>An INR of 2.5-3.5 for mechanical prosthetic
     valves or recurrent systemic thromboembolism</span></li>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>INR of 2.0-3.0 for most others (uncomplicated
     DVT/PE).</span></li>
</ul>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Information about the patient's past warfarin dosing history will
help you titrate appropriately. Congestive heart failure, liver disease,
vitamin K deficiency and certain medications influence warfarin response.
Tailor the duration of warfarin therapy to the individual and the indication –
usually three months to life.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Hirsh J, Dalen J, et al.&nbsp; Oral anticoagulants: mechanism of
action, clinical effectiveness, and optimal therapeutic range.&nbsp; Chest.
2001 Jan;119(1 Suppl):8S-21S.</span></i></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_OUTPATIENT_THERAPY_FOR_1"></a><a name="_OUTPATIENT_THERAPY_FOR"></a>OUTPATIENT
THERAPY FOR VENOUS THROMBOEMBOLISM</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Indications:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Clinically stable patients with DVT or PE
documented with imaging study.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Patients must be motivated and interested
in home self-injection and frequent follow-up.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Contraindications:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Co-morbid conditions: Active peptic ulcer
disease, bleeding in last 14 days, brain metastases, CVA in last 10 days,
blindness, CNS or cord injury/surgery in last 10 days, family bleeding diathesis,
patient weight &lt;35 kg, platelets &lt; 80K or fall of &gt; 40%.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Anesthesia: Spinal or epidural anesthesia
in past 3 days.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Medication conflicts: prior sensitivity to
heparin, concomitant thrombolytic therapy, need for high-dose NSAIDs other than
ibuprofen, naproxen, or Celebrex®.&nbsp; Vioxx® may result in warfarin
sensitivity.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Cognition problems: inability to maintain
diary, inject medications, reliably follow medication schedules, recognize change
in health status, or understand directions from home health team.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Initial therapy: </span></b><span style='font-size:11.0pt;
color:black'>enoxaparin (1 mg/kg SQ q12h) plus warfarin (5 mg PO qhs; 7.5 mg PO
qhs if &gt; 85 kg).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Maintenance algorithm:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Continue enoxaparin until patient has
received five days of enoxaparin and has two consecutive INR &gt; 2.0.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Adjust warfarin to keep INR in desired
range.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Check PT/INR frequently after day 2 until
patient is on stable dose of warfarin.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_SUPRATHERAPEUTIC_PT/PTT"></a>SUPRATHERAPEUTIC PT/PTT</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Differential diagnosis</span></b><span style='font-size:11.0pt;
color:black'> <b>for prolonged PT:</b> warfarin, liver disease, poor nutrition,
vitamin K deficiency (antibiotics, nutritional, fat malabsorption), deficiency
or inhibitor for factors II, V, VII, or X, DIC, heparin bolus.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Differential diagnosis</span></b><span style='font-size:11.0pt;
color:black'> <b>for prolonged PTT:</b> heparin, congenital deficiency of VIII,
IX, XI, von Willebrand’s disease, anti-phospholipid antibody, inhibitor to any
factor except VII, liver disease, DIC.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Use oral vitamin K to correct mild to moderate PT prolongation.
Correction occurs within 10-12 hours. Subcutaneous vitamin K is as good as IV
vitamin K, minus the risk of anaphylaxis.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>FFP lasts 4-6 hours (need to give concomitant vitamin K).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>5.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Bebulin is a plasma-derived concentrate of factors II, VII, IX,
and X.&nbsp; It should be used in life threatening bleeds associated with
warfarin.&nbsp; Dose Bebulin ~50 U/kg IV push (need to give concomitant vitamin
K).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>6.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>For heparin associated bleeding:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Unfractionated heparin: Protamine 1 mg for
every 100 units heparin given. Dose by adding the amount given during each
prior hour divided by 2 <sup>number of hours back</sup>.&nbsp; For example, a
patient on a heparin drip at 500 units/hour for 3 hours (without a bolus) would
have approximately (500/2<sup>0</sup>)+(500/2<sup>1</sup>)+(500/2<sup>2</sup>)
=&nbsp; 500 + (500/2) + (500/4) = 875 units of circulating heparin.&nbsp;
Therfore, the patient should be given 8-9 mg of protamine.</span></p>

<p class=MsoBodyText2 style='margin-left:.5in;text-indent:-.5in'><span
style='font-family:Symbol'>·</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>Enoxaparin: 1mg:1mg. Protamine may reverse 40-50% of the drug effect.</p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table border=0 cellspacing=0 cellpadding=0 style='margin-left:41.4pt;
 border-collapse:collapse;'>
 <tr>
  <td width=125 valign=top style='width:74.7pt;border-top:black 1.5pt;
  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;
  border-style:solid;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>INR</span></b></p>
  </td>
  <td width=95 valign=top style='width:57.25pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Bleeding</span></b></p>
  </td>
  <td width=324 valign=top style='width:194.15pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Vitamin K</span></b></p>
  </td>
  <td width=127 valign=top style='width:75.9pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>FFP</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:74.7pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Normal – 5.9</span></p>
  </td>
  <td width=95 valign=top style='width:57.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>None</span></p>
  </td>
  <td width=324 valign=top style='width:194.15pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Not indicated</span></p>
  </td>
  <td width=127 valign=top style='width:75.9pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Not indicated</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:74.7pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>6.0 – 9.9</span></p>
  </td>
  <td width=95 valign=top style='width:57.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>None</span></p>
  </td>
  <td width=324 valign=top style='width:194.15pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Oral: 0.5 – 2.5 mg</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>SC: 0.5 – 1.0 mg</span></p>
  </td>
  <td width=127 valign=top style='width:75.9pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Not indicated</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:74.7pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>&gt; 10</span></p>
  </td>
  <td width=95 valign=top style='width:57.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>None</span></p>
  </td>
  <td width=324 valign=top style='width:194.15pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>SC: 3 mg total, in divided doses of 1 mg</span></p>
  </td>
  <td width=127 valign=top style='width:75.9pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Not indicated</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:74.7pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>&gt; 20</span></p>
  </td>
  <td width=95 valign=top style='width:57.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Yes</span></p>
  </td>
  <td width=324 valign=top style='width:194.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>SC: 10 mg</span></p>
  </td>
  <td width=127 valign=top style='width:75.9pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>10 – 20 cc/kg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h1><a name="_UREMIC_BLEEDING"></a>UREMIC BLEEDING</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Tips:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Keep hematocrit &gt; 24%</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Keep platelets &gt; 75K</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>FFP may be helpful if bleeding occurs in
the setting of an elevated INR</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Therapies:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Dialysis</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Conjugated estrogen 0.6 mg/kg IV QD x 5
days</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>DDAVP 0.3 mcg/kg IV q12 hours x 2</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h1><a name="_BLOOD_PRODUCTS_–"></a><span style='font-size:11.0pt;color:black'>&nbsp;</span><br
clear=all style='page-break-before:always'>
BLOOD PRODUCTS – COMPONENTS</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Premeds:</span></b><span style='font-size:11.0pt;color:black'>
consider pre-medicating with Benadryl 25 mg PO/IV and Tylenol 650 mg PO/PR
before each unit.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Packed red blood cells (PRBC):</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Most plasma removed. One unit should raise the hematocrit by 3
points or hemoglobin by 1 g/dL.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Leuko-poor/leuko-filtered red blood cells have most
WBCs removed to make it less antigenic. Use in patients prone to transfusion
reactions and in patients requiring multiple transfusions (bone marrow
transplant, leukemia, chemotherapy).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Washed red blood cells have WBC almost all
removed. Use as for leuko-poor RBC; note that they are more expensive.&nbsp;
Used for patients with allergic reaction to transfusions.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Irradiated blood cells have lymphocytes killed, decreasing
likelihood of graft-versus host disease (GVHD) in bone marrow transplant
patients.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>CMV
negative blood used for patients who are CMV negative and are pre-transplant or
post-transplant.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Platelets:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>A 6-pack should&nbsp; ideally raise
platelet count by 50-60K; For dysfunctional platelets (e.g. in uremia), DDAVP
is usually given at 0.3 mcg/kg IV q12-24 hours x 2. Do not correct platelets
for paracentesis.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Indications:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Platelets &lt; 10-20K for non-bleeding
patient.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Platelets &lt; 50K for bleeding, pre-op,
or pre-procedure.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Platelets &lt; 75K for uremic bleeding
patients.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Platelets &lt; 100K for CNS or intraocular
bleed.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Cross-matched platelets may be used when
patient has been sensitized to random-donor platelets and no longer bumps their
platelet counts after transfusion; cross-matching typically takes at least 1-2
days as well as lab medicine approval at most institutions.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Always check a 1 hour post-transfusion
platelet count to ensure a response and to monitor for alloimmunization.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoBodyText2 style='margin-left:.25in;text-indent:-.25in'>4.<span
style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b>Fresh frozen plasma
(FFP):</b></p>

<p class=MsoBodyText style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>A
high PT is frequently encountered in end-stage liver disease. It is generally
okay to leave a high PT alone when a patient is not bleeding. For those with
refractory bleeding, use an FFP drip—the half-life of FFP is about 4-6 hours.</span></p>

<p class=MsoBodyText style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>FFP
is indicated if the PT &gt; 18 seconds and is associated with bleeding or
planned procedures.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h2 style='margin-left:.25in;text-indent:-.25in'><span style='font-size:11.0pt;
font-style:normal'>5.</span><span style='font-size:7.0pt;font-style:normal'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt;font-style:normal'>Cryoprecipitate:</span></b></h2>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Contains factor VIII, von Willebrand
factor, and fibrinogen.</span></p>

<p class=MsoBodyTextIndent style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Use
is generally reserved for patients with quantitative fibrinogen deficiency (<i>e.g.</i>
DIC) and qualitative fibrinogen deficits (<i>e.g.</i> acquired dysfibrinogenemia
associated with liver disease). Its use in patients with hemophilia A (factor
VIII deficiency) and von Willebrand disease has been supplanted by the use of
specific factor products that are safer and more efficacious.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Advantage: you can replete with less
volume than FFP.</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt;color:black'>&nbsp;</span></b></p>

<h6><i><span style='font-size:9.0pt;font-family:Arial;font-weight:normal;
text-decoration:none;'>Churchill WH.&nbsp; Transfusion
therapy. In: Scientific American Medicine.&nbsp; Edited by Federman D.&nbsp;
New York: Scientific American, 1999.</span></i><span style='font-size:11.0pt;
font-weight:normal'><br clear=all style='
page-break-before:always'>
</span></h6>

<h6><span style='font-size:11.0pt;font-weight:normal'>&nbsp;</span></h6>

<h1><a name="_BLOOD_PRODUCTS_–_1"></a>BLOOD PRODUCTS – COMPLICATIONS</h1>

<h6>&nbsp;</h6>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Work-up: </span></b><span style='font-size:11.0pt;color:black'>for
all transfusion reactions consider a workup for a hemolytic reaction: blood
cultures and hemolysis labs, including purple top for Coombs and red top for
repeat type and cross.&nbsp; The blood bank is required to investigate and will
help. The different types of reactions are listed below.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Acute hemolytic transfusion reaction:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Preexisting anti-RBC antibodies in the
recipient hemolyze donated blood. Usually caused by ABO incompatibility due to
a clerical error. Fever and hypotension occur early in the transfusion; chills,
flank pain, and dyspnea may occur.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Stop blood product immediately, as little
as 30 cc can be fatal.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Provide hemodynamic and renal support.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Maintain diuresis with IV fluids and
furosemide; consider alkalinization of urine with bicarbonate to prevent renal
failure. Watch K<sup>+</sup>, CK.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Delayed hemolytic transfusion reaction:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>An extravascular immune-mediated process
mediated by noncomplement-binding IgG. Ideally, the “screen” portion of the
type and screen will identified patients susceptible to this
complication.&nbsp; Fever, jaundice, and anemia occur 2 days to 2 weeks after
transfusion.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Anaphylaxis:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>This is different from an acute hemolytic
reaction.&nbsp; Interestingly, the reaction is not IgE mediated, but caused by
immune-complex activation of complement – by “anaphylatoxins.”&nbsp; Symptoms
are anaphylactoid, occur early in transfusion, and include laryngeal edema.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Stop the transfusion</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Give epinephrine and steroids</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Wash subsequent blood products, and avoid
FFP</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>5.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Bacterial contamination:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Look for endotoxemia—the onset of high
fever/shock within 4 hours of transfusion. Platelets are far more likely to be
contaminated with bacteria than blood, because they are stored are room
temperature.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>6.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Acute lung injury:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i><span
style='font-size:11.0pt;color:black'>i.e.</span></i><span style='font-size:
11.0pt;color:black'> “noncardiogenic pulmonary edema”. Also termed
“TRALI”—transfusion-related acute lung injury.&nbsp; This is caused by donor
antibodies against recipient WBCs. Respiratory failure occurs within 6 hours of
transfusion and treatment is supportive.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>7.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Febrile nonhemolytic transfusion reaction:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>This is characterized by fever &gt; 1</span><span
style='font-size:11.0pt;font-family:Symbol;color:black'>°</span><span
style='font-size:11.0pt;color:black'> C during or within 2 hours of completing
transfusion. It occurs with 1 in 5 platelet transfusion reactions and is of
limited clinical significance. It is questionable whether it is necessary to
discontinue the transfusion. Caused by antibodies against foreign donor
leukocyte antigens.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>8.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Urticarial reaction:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Some say it is okay to continue
transfusion if the patient responds to antihistamines. Again, this is different
from—and does not progress to—an anaphylactiod reaction.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>For nonhemolytic reactions:</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Benadryl 25-50 mg and Tylenol 650 mg for
mild transfusion reactions.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Hydrocortisone 50-100 mg IV for moderate
and severe reactions.</span></p>

<h5 align=left style='text-align:left'><span style='font-weight:normal'>&nbsp;</span></h5>

<h5 align=left style='text-align:left'><span style='font-weight:normal'>&nbsp;</span></h5>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_NEUTROPENIC_FEVER:_ABSOLUTE_1"></a><a
name="_NEUTROPENIC_FEVER:_ABSOLUTE"></a>NEUTROPENIC FEVER: ABSOLUTE NEUTROPHIL
COUNT &lt; 500</h1>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>If patient has HIV, see <i><a href="HospH2002_C10.htm#HIV_Fever">Infectious
Diseases: HIV and fever</a></i>.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoHeading7 style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-weight:normal;text-decoration:none;'>2.</span><span style='font-size:7.0pt;font-weight:normal;text-decoration:
none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;text-decoration:none;'>Non-bone marrow
transplant patients:</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Obtain blood culture x 2, urine culture,
sputum Gram stain and culture, <i>C. difficile</i> toxin if patient has been on
antibiotics, and CXR.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Order neutropenic precautions (no rectals,
no flowers, no fruit), neutropenic diet, mouth care with Peridex 10 cc sw/sp
bid, Nystatin 10 cc sw/sw qid or Mycelex troche 1 qid, and Tylenol 650 mg q 4-6
hour prn.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Consider monotherapy with broad-spectrum
antibiotics such as ceftazidime, cefipime or anti-pseudomonal beta-lactam.
Cover for Gram negative bacteria including Pseudomonas.&nbsp; Also cover Gram
positives such as Staph aureus and Strep viridans.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>If prolonged neutropenia, consider fungal
infection and adding amphotericin B (typically 1 mg/kg IV qd).</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>For nosocomial acquisition, suspected IV
catheter infection, known colonization with MRSA/PRSP, (+) blood culture for
Gram positive cocci, or a hypotensive patient, consider covering MRSA by adding
vancomycin.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt'>-</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>Double-cover documented Pseudomonas by
adding an aminoglycoside or a fluoroquinolone, such as ciprofloxacin. The
fluoroquinolone is preferable given the renal toxicity of aminoglycosides.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<h6 style='margin-left:.25in;text-indent:-.25in'><span style='font-size:11.0pt;
font-weight:normal;text-decoration:none;'>3.</span><span
style='font-size:7.0pt;font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;text-decoration:
none;'>Bone marrow transplant patients:</span><span
style='font-size:11.0pt;font-weight:normal;text-decoration:none;'> the guidelines above still apply, except for the following:</span></h6>

<h6 style='margin-left:.5in;text-indent:-.25in'><span style='font-size:11.0pt;
font-family:Symbol;font-weight:normal;text-decoration:none;'>·</span><span
style='font-size:7.0pt;font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
font-weight:normal;text-decoration:none;'>Most hospitals
that have a bone marrow transplant unit have an antibiotic algorithm that you
should follow when treating bone marrow transplant patients with neutropenic
fever.</span></h6>

<h6 style='margin-left:.5in;text-indent:-.25in'><span style='font-size:11.0pt;
font-family:Symbol;font-weight:normal;text-decoration:none;'>·</span><span
style='font-size:7.0pt;font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
font-weight:normal;text-decoration:none;'>The patients most likely
to suffer from full blown sepsis syndrome are those who are
penicillin-allergic.</span></h6>

<p class=MsoNormal style='margin-left:.25in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_SICKLE_CELL_PAIN"></a>SICKLE CELL PAIN CRISIS</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>Your hospital
staff typically know these patients well.&nbsp; Often, the patient’s primary physician
has contracted with the patient for an individualized pain protocol.&nbsp;
Consider consultation with the hematologist or pain service to get the exact
details (if they exist).&nbsp; Don’t be surprised by massive opiate tolerance
and the need to rapidly escalate the analgesia dose required for relief:
remember, physicians typically under-treat pain.&nbsp; Unlike most opioids,
such as morphine and oxycodone, codeine and hydrocodone have ceilings beyond
which increasing doses will not result in increasing analgesia.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Tips:</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Stroke, MI, persistent priapism, or
intractable pain characterize acute vaso-occlusive crises. Exchange transfusion
is indicated in these cases. Also, multi-organ failure requires urgent exchange
transfusion.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>If patient with frequent episodes of pain
crisis, consider hydroxyurea as prophylaxis.</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;'><span
     style='font-size:11.0pt'>In the past, the dogma for treating sickle cell
     crises called for aggressive fluids, oxygen, and even bicarbonate
     infusions as methods to reverse the “sickling” process in the red blood
     cells.&nbsp; However, we have since learned that the event that led to the
     sickle crisis (and thus the “sickling”) has already occurred by the time
     the patient comes into the ER.&nbsp; Therefore, these measures are
     unlikely to be helpful and may be harmful (see below).</span></li>
</ul>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h4 style='margin-left:.25in;text-indent:-.25in'><span style='font-size:11.0pt;
font-weight:normal'>2.</span><span style='font-size:7.0pt;font-weight:normal'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><span style='font-size:11.0pt'>Orders:</span></h4>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>IV: moderate hypotonic (<i>e.g. D<sub>5</sub>½NS</i>)
hydration.&nbsp; <i>Aggressive hydration can lead to or exacerbate acute chest
syndrome</i>.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>DIET: NPO; advance diet as tolerated.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>NURSING: O<sub>2</sub> 0-4 L/min by NC.
(If respiratory status is compromised, remember acute chest syndrome. A new
pulmonary infiltrate, fever, chest pain, cough, tachypnea and cough are
characteristic).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>LAB: CBC, reticulocyte count, cultures,
electrolytes, BUN, creatinine, bilirubin, U/A, CXR.&nbsp; Draw red-top tube for
type and hold. (If patient is to be transfused, alert the blood bank that the
patient has sickle cell disease; these patients will be screened more
thoroughly to avoid alloimmunization associated with frequent transfusions).</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>MEDS:Folic acid 1 mg PO QD and analgesic <i>du
jour.&nbsp; </i>Avoid Demerol: these patients will inevitably require huge
doses, and are at greatly increased risk of seizures.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;
color:black'>Try to determine precipitating factor(s): stress, dehydration,
drug use, infection, hypoxia, MI, etc. Although, remember that many of these
patients come in and out of the hospital for &quot;routine&quot; pain crises
without specific precipitants. While pain crises often present with
non-specific elevations in WBC and low-grade fevers, there always is the
potential for something bad to be going on. Therefore complete work up of
concomitant infection is important.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Acute chest syndrome:</span></b><span style='font-size:11.0pt;
color:black'> This is one of the dreaded complications of sickle cell disease
and a leading cause of death in adults with this disease.&nbsp; You should
think of this diagnosis in any patient with cough, chest pain, wheezing,
shortness of breath, fever, and/or new infiltrate on CXR who has a history of
sickle cell disease.&nbsp; Etiology is not fully known, but thought to involve
micro/macro vascular infarction, pulmonary fat emboli, and concurrent
viral/bacterial infection.&nbsp; Management primarily consists of supportive
care, bronchodilators, treatment of coexisting infection, and transfusions if
needed.&nbsp; In addition, a simple transfusion may be adequate, but if the
patient’s clinical situation worsens an exchange transfusion may be needed.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Vichinsky EP, Neumayr LD, et al.&nbsp;&nbsp; Causes and outcomes
of the acute chest syndrome in sickle cell disease. National Acute Chest
Syndrome Study Group.&nbsp; N Engl J Med. 2000 Jun 22;342(25):1855-65.</span></i></p>

<h5 align=left style='text-align:left'><span style='font-weight:normal'>&nbsp;</span></h5>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_THROMBOCYTOPENIA"></a>THROMBOCYTOPENIA</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>1.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Defined</span></b><span style='font-size:11.0pt;color:black'> as
platelet count &lt; 150K. Generally, platelets &gt; 50K are not associated with
significant bleeding, and spontaneous bleeding rarely happens with platelets
&gt;10-20K in the absence of coagulopathy or qualitative platelet defect.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Avoid intramuscular injections, rectal
exams, suppositories, and enemas.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Avoid drugs that interfere with platelet
function (e.g. NSAIDs/ASA, certain beta-lactam antibiotics).</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>2.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>History:</span></b><span style='font-size:11.0pt;color:black'>
“B”-symptoms (such as fevers, night sweats, weight loss), GI bleed, epistaxis.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>3.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Physical examination:</span></b><span style='font-size:11.0pt;
color:black'> look for lymphadenopathy, splenomegaly, ecchymoses, petechiae,
purpura. Petechiae indicate a significant risk for intracerebral hemorrhage.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>4.</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:11.0pt;
color:black'>Labs:</span></b><span style='font-size:11.0pt;color:black'>
peripheral smear, PT/PTT, LDH (MAHA), BUN/Cr (HUS/TTP). Get HIV, ANA when
indicated, and consider toxoplasmosis, EBV, and CMV serology if
lymphadenopathy, splenomegaly, or “B”-symptoms are detected.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h6 style='margin-left:.25in;text-indent:-.25in'><span style='font-size:11.0pt;
font-weight:normal;text-decoration:none;'>5.</span><span
style='font-size:7.0pt;font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt;text-decoration:
none;'>Etiologies:</span></h6>

<h4 style='margin-left:.5in;text-indent:-.5in'><span style='font-size:11.0pt;
font-family:Symbol;font-weight:normal'>·</span><span style='font-size:7.0pt;
font-weight:normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Decreased Production</span></h4>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Aplastic anemia</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Megaloblastic anemia: B12 or folate
deficiency</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Hematologic malignancies: myelodysplasia,
leukemia, myeloma</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Marrow infiltration: lymphoma,
myelofibrosis, metastatic tumor, TB, Gaucher's disease</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Drug-induced: EtOH, thiazides, estrogens,
Septra, chemotherapy, cimetidine, famotidine</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Paroxysmal nocturnal hemoglobinuria (PNH):
rare and associated with pancytopenia.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Infections: mono, influenza, rubella, hemorrhagic
fever, sepsis.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span
style='font-size:11.0pt;color:black'>Increased Destruction</span></b><span
style='font-size:11.0pt;color:black'>: classically associated with large
platelets on the smear.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Immune mediated:</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>ITP: sending platelet associated antibody
has low sens/spec, treat with steroids, IVIG, splenectomy</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Neoplasia-associated: CLL</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Drug-induced: quinidine, heparin (HIT),
rifampin, sulfa, indomethacin, gold</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>SLE, RA</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>HIV-associated thrombocytopenia</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Post-transfusion purpura</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
style='font-size:11.0pt;color:black'>-</span><span style='font-size:7.0pt;
color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Non-immune mediated:</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>DIC: increased PT/PTT and D-dimers,
decreased platelet/fibrinogen, hemolytic anemia, prosthetic valves.</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>HUS</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>TTP: always increased LDH. Decreased
platelet, and normal PT/PTT.</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Pre-ecclampsia/ecclampsia</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Toxic shock syndrome</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Vasculitis</span></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-1.0in'><span
style='font-size:11.0pt;font-family:"Courier New";color:black'>o</span><span
style='font-size:7.0pt;color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;color:black'>Infections: rickettsia, CMV, EBV, malaria,
sepsis, etc.</span></p>

<h4 style='margin-left:.5in;text-indent:-.5in'><span style='font-size:11.0pt;
font-family:Symbol;font-weight:normal'>·</span><span style='font-size:7.0pt;
font-weight:normal'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt'>Sequestration</span><span style='font-size:11.0pt;
font-weight:normal'>: Hypersplenism</span></h4>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b><span style='font-size:
11.0pt'>Pseudo-thrombocytopenia</span></b><span style='font-size:11.0pt'>:
Blood clumping on CBC, need to check smear to rule out</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>George JN, Raskob GE, et al.&nbsp; Drug-induced thrombocytopenia:
a systematic review of published case reports.</span></i></p>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Ann Intern Med. 1998 Dec 1;129(11):886-90.</span></i></p>

<p class=MsoNormal><b><span style='font-size:12.0pt;font-family:Arial;
color:black'>&nbsp;</span></b></p>

<b><span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span></b>

<h1><a name="_HEPARIN-INDUCED_THROMBOCYTOPENIA_(HIT)"></a>HEPARIN-INDUCED
THROMBOCYTOPENIA (HIT)</h1>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h5 align=left style='margin-left:.25in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>1.</span><span style='font-size:7.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:
11.0pt;font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>There are primarily two types of HIT:</span></h5>

<p class=MsoNormal>&nbsp;</p>

<table border=0 cellspacing=0 cellpadding=0 width=638 style='width:382.5pt;
 margin-left:23.4pt;border-collapse:collapse;'>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:black 1.5pt;
  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;
  border-style:solid;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:#3366FF'>&nbsp;</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt;color:#3366FF'>Type 1</span></b></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt;color:#3366FF'>Type 2</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Frequency</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>10-20%</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>1-3%</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Timing</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>1-4 days</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>5-10 days</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Nadir of
  platelet count</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>100,000</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>30-55,000</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Antibody
  mediated</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>No</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Yes</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Thromboembolic
  sequelae</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>None</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>30-80%</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Hemorrhagic
  sequelae</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>None</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext .5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Rarely</span></p>
  </td>
 </tr>
 <tr>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;border-right:
  solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Management</span></p>
  </td>
  <td width=135 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Observe</span></p>
  </td>
  <td width=255 valign=top style='width:153.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;color:black'>Discontinue heparin
  and start alternate anticoagulant.</span></p>
  </td>
 </tr>
</table>

<h5 align=left style='text-align:left'>&nbsp;</h5>

<h5 align=left style='margin-left:.25in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>2.</span><span style='font-size:7.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:
11.0pt;font-family:"Times New Roman";text-decoration:none;'>Diagnosis:
</span><span style='font-size:11.0pt;font-family:"Times New Roman";font-weight:
normal;text-decoration:none;'>think of this diagnosis in
your hospitalized patients whose platelet count starts dropping.</span></h5>

<h5 align=left style='margin-left:.5in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol;color:windowtext;font-weight:normal;
text-decoration:none;'>·</span><span style='font-size:7.0pt;
font-family:"Times New Roman";color:windowtext;font-weight:normal;text-decoration:
none;'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>You can diagnose HIT type 2 by
sending platelet factor 4 antibody, although this syndrome is primarily a
clinical diagnosis.</span></h5>

<h5 align=left style='text-align:left'><span style='font-size:11.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;</span></h5>

<h5 align=left style='margin-left:.25in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>3.</span><span style='font-size:7.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:
11.0pt;font-family:"Times New Roman";text-decoration:none;'>Incidence:
</span><span style='font-size:11.0pt;font-family:"Times New Roman";font-weight:
normal;text-decoration:none;'>HIT occurs less frequently now
with the increased use of low molecular weight heparin.</span></h5>

<h5 align=left style='text-align:left'><span style='font-size:11.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;</span></h5>

<h5 align=left style='margin-left:.25in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>4.</span><span style='font-size:7.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:
11.0pt;font-family:"Times New Roman";text-decoration:none;'>Complications:
</span><span style='font-size:11.0pt;font-family:"Times New Roman";font-weight:
normal;text-decoration:none;'>the thrombotic complications
can be arterial or venous and often occur at sites of preexisting pathology.</span></h5>

<p class=MsoNormal>&nbsp;</p>

<h5 align=left style='margin-left:.25in;text-align:left;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:"Times New Roman";font-weight:normal;
text-decoration:none;'>5.</span><span style='font-size:7.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:
11.0pt;font-family:"Times New Roman";text-decoration:none;'>Treatment:
</span><span style='font-size:11.0pt;font-family:"Times New Roman";font-weight:
normal;text-decoration:none;'>includes stopping all heparin
products (including heparin flushes and coated catheters), and instituting
alternate anticoagulation, as these patients are at increased risk of
thrombosis.&nbsp; Choices include danaparoid (a heparinoid) or lepirudin and
argatroban (direct thrombin inhibitors).</span></h5>

<h5 align=left style='text-align:left'><span style='font-size:11.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;</span></h5>

<p class=MsoNormal><i><span style='font-size:9.0pt;font-family:Arial'>Brieger
DB, Mak KH, Kottke-Marchant K, Topol EJ.&nbsp;&nbsp; Heparin-induced
thrombocytopenia.&nbsp; J Am Coll Cardiol. 1998 Jun;31(7):1449-59.</span></i></p>

<h5 align=left style='text-align:left'><span style='font-size:11.0pt;
font-family:"Times New Roman";font-weight:normal;text-decoration:none;'>&nbsp;</span></h5>

<h5 align=left style='text-align:left'><span style='font-weight:normal'>&nbsp;</span></h5>

<span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span>

<h1><a name="_BONE_MARROW_TRANSPLANT"></a>BONE MARROW TRANSPLANT (BMT) –
POTENTIAL COMPLICATIONS</h1>

<p class=MsoNormal><span style='font-size:11.0pt'>&nbsp;</span></p>

<table border=0 cellspacing=0 cellpadding=0 style='margin-left:9.9pt;
 border-collapse:collapse;'>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:black 1.5pt;
  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;
  border-style:solid;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt;color:#3366FF'>Days
  post-BMT</span></b></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt;color:#3366FF'>Complication</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>-7 to 21</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Toxicology of preparative
  regimens (nausea, vomiting, diarrhea, alopecia, mucositis, renal failure,
  skin breakdown, ARDS, cardiomyopathy)</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>0 to 21</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>HSV reactivation, hepatic
  veno-occlusive disease</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>0 to 28</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Diffuse alveolar
  hemorrhage, particularly at engraftment</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>0 to 49</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Bacterial and fungal
  infections</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>28 to 70</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>CMV infection</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>14 to 100</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Acute GVHD</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>49 to 100</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Interstitial pneumonitis</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 valign=top style='width:90.6pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>100 to 180</span></p>
  </td>
  <td width=631 valign=top style='width:378.3pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=MsoNormal><span style='font-size:11.0pt'>Chronic GVHD, VZV, PCP</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<h1><a name="_BMT_–_ACUTE"></a>BMT – ACUTE GRAFT VS. HOST DISEASE STAGING AND
GRADING</h1>

<p class=MsoNormal>&nbsp;</p>

<table border=0 cellspacing=0 cellpadding=0 width=758 style='width:454.5pt;
 margin-left:9.9pt;border-collapse:collapse;'>
 <tr>
  <td width=70 valign=top style='width:42.0pt;border-top:black 1.5pt;
  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;
  border-style:solid;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Stage</span></b></p>
  </td>
  <td width=219 valign=top style='width:131.25pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Skin</span></b></p>
  </td>
  <td width=221 valign=top style='width:132.75pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Liver (total bilirubin)</span></b></p>
  </td>
  <td width=248 valign=top style='width:148.5pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>GI</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:42.0pt;border-top:none;border-left:solid black 1.5pt;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+</span></p>
  </td>
  <td width=219 valign=top style='width:131.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>maculopapular rash</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>on &lt; 25 % of BSA</span></p>
  </td>
  <td width=221 valign=top style='width:132.75pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2-3 mg/dl</span></p>
  </td>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>diarrhea 500 – 1000 cc/day </span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:42.0pt;border-top:none;border-left:solid black 1.5pt;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+</span></p>
  </td>
  <td width=219 valign=top style='width:131.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>maculopapular rash</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>on 25-50 % of BSA</span></p>
  </td>
  <td width=221 valign=top style='width:132.75pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>3-6 mg/dl</span></p>
  </td>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>diarrhea 1000 – 1500 cc/day </span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:42.0pt;border-top:none;border-left:solid black 1.5pt;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>3+</span></p>
  </td>
  <td width=219 valign=top style='width:131.25pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>generalized erythroderma</span></p>
  </td>
  <td width=221 valign=top style='width:132.75pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>6-15 mg/dl</span></p>
  </td>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>diarrhea &gt; 1500 cc/day </span></p>
  </td>
 </tr>
 <tr>
  <td width=70 valign=top style='width:42.0pt;border-top:none;border-left:solid black 1.5pt;
  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>4+</span></p>
  </td>
  <td width=219 valign=top style='width:131.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>generalized erythroderma</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>and desquamation</span></p>
  </td>
  <td width=221 valign=top style='width:132.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>&gt; 15 mg/dl</span></p>
  </td>
  <td width=248 valign=top style='width:148.5pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>severe abdominal pain ± ileus</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>Use staging
information above to determine clinical grade on chart below:</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table border=0 cellspacing=0 cellpadding=0 style='margin-left:9.9pt;
 border-collapse:collapse;'>
 <tr>
  <td width=138 valign=top style='width:82.65pt;border-top:black 1.5pt;
  border-left:black 1.5pt;border-bottom:windowtext .5pt;border-right:windowtext .5pt;
  border-style:solid;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Clinical grade</span></b></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Skin</span></b></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Liver</span></b></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>GI</span></b></p>
  </td>
  <td width=373 valign=top style='width:223.95pt;border-top:solid black 1.5pt;
  border-left:none;border-bottom:solid windowtext .5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:11.0pt;color:#3366FF'>Decrease in clinical performance</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=138 valign=top style='width:82.65pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>I</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+ to 2+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>0</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>0</span></p>
  </td>
  <td width=373 valign=top style='width:223.95pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>None</span></p>
  </td>
 </tr>
 <tr>
  <td width=138 valign=top style='width:82.65pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>II</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+ to 3+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+</span></p>
  </td>
  <td width=373 valign=top style='width:223.95pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Mild</span></p>
  </td>
 </tr>
 <tr>
  <td width=138 valign=top style='width:82.65pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black .25pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>III</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>1+ to 3+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+ to 3+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black .25pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+ to 3+</span></p>
  </td>
  <td width=373 valign=top style='width:223.95pt;border-top:none;border-left:
  none;border-bottom:solid black .25pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Marked</span></p>
  </td>
 </tr>
 <tr>
  <td width=138 valign=top style='width:82.65pt;border-top:none;border-left:
  solid black 1.5pt;border-bottom:solid black 1.5pt;border-right:solid black .25pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>IV</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+ to 4+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+ to 4+</span></p>
  </td>
  <td width=90 valign=top style='width:53.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.5pt;border-right:solid black .25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>2+ to 4+</span></p>
  </td>
  <td width=373 valign=top style='width:223.95pt;border-top:none;border-left:
  none;border-bottom:solid black 1.5pt;border-right:solid black 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:11.0pt'>Extreme</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoFootnoteText><i><span style='font-size:9.0pt;font-family:Arial;
color:black'>Armitage JO. Bone marrow transplantation. N Engl J Med. 1994 Mar
24;330(12):827-38.</span></i></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<b><span style='font-size:14.0pt;font-family:"Times New Roman";color:blue;'><br clear=all
style='page-break-before:always'>
</span></b>

<h1><a name="_ONCOLOGIC_EMERGENCIES"></a>ONCOLOGIC EMERGENCIES</h1>

<p class=MsoFootnoteText><b><span style='font-size:12.0pt;font-family:Arial'>&nbsp;</span></b></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>1.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Cord compression:</span></b><span
style='font-size:11.0pt'> see <i><a href="HospH2002_C12.htm#_CORD_COMPRESSION">Neurology:
Cord compression</a> </i>for more details.&nbsp; Remember early treatment is
key—dexamethasone, radiation, and neurosurgical evaluation.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>2.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Neutropenic fever:</span></b><span
style='font-size:11.0pt'> see <i><a href="#_NEUTROPENIC_FEVER:_ABSOLUTE_1">Hematology/Oncology:
Neutropenic fever</a>.</i></span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>3.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Cerebral metastases:</span></b><span
style='font-size:11.0pt'> can present as headache, seizures, altered mental
status, or focal deficit.&nbsp; Common in breast and lung cancer.&nbsp;
Diagnose with head CT.&nbsp; Treat with dexamethasone, radiation, and possible
surgery.&nbsp; With edema, mass effect, and/or midline shift, consider measures
to control the rise in intracranial pressure (ICP) such as mannitol and
hyperventilation.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>4.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Carcinomatous meningitis:</span></b><span
style='font-size:11.0pt'> may present as seizures, focal neurologic deficits,
peripheral neuropathy, or altered mental status.&nbsp; Occurs most often with breast
cancer, lymphoma, and leukemia.&nbsp; Diagnose&nbsp; with spinal fluid
cytology.&nbsp;&nbsp; Treat with intrathecal chemotherapy or whole brain
radiation.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>5.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Superior vena cava (SVC) syndrome:</span></b><span
style='font-size:11.0pt'> presents with facial and/or upper extremity edema as well
as dyspnea on exertion.&nbsp; Commonly seen with lung cancer and
lymphoma.&nbsp; Diagnose with CT scan (gold standard). &nbsp;Treat with
radiation and/or chemotherapy based on tumor type.&nbsp; Surgery is often risky
and dangerous.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>6.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Hypercalcemia</span></b><span
style='font-size:11.0pt'>: Presents gradually with fatigue, anorexia,
constipation, polyuria, and confusion.&nbsp; Can occur with squamous cell
carcinomas, breast cancer, small cell lung cancer, and myeloma.&nbsp; Treat
with hydration, lasix, calcitonin and pamidronate if needed. See also <i><a
href="HospH2002_C5.htm#Hyperca">Acid-base/Electrolytes: Hypercalcemia</a></i>.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>7.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Tumor lysis syndrome:</span></b><span
style='font-size:11.0pt'> findings include </span><span style='font-size:11.0pt;
font-family:Symbol'>­</span><span style='font-size:11.0pt'> potassium, </span><span
style='font-size:11.0pt;font-family:Symbol'>­</span><span style='font-size:
11.0pt'> phosphorous, </span><span style='font-size:11.0pt;font-family:Symbol'>­</span><span
style='font-size:11.0pt'> uric acid, </span><span style='font-size:11.0pt;
font-family:Symbol'>­</span><span style='font-size:11.0pt'> creatinine, and </span><span
style='font-size:11.0pt;font-family:Symbol'>¯</span><span style='font-size:
11.0pt'> calcium.&nbsp; Often occurs with tumors that are bulky and very
chemotherapy-sensitive.&nbsp;&nbsp; Seen often in Burkitt’s lymphoma.&nbsp;
Prevent with hydration and allopurinol.&nbsp; If patient develops syndrome,
treat electrolyte abnormalities and continue hydration and allopurinol.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>8.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Hyperviscosity:</span></b><span
style='font-size:11.0pt'> patients present with nonspecific CNS symptoms such
as headache, dizziness, somnolence, and blurry vision.&nbsp; More often occurs
in patient with myeloma, Waldenstrom’s macroglobulinemia, and polycythemia
vera.&nbsp;&nbsp; Obtain CSF, head CT to rule out other CNS processes. Treat
with hydration, phlebotomy (for polycythemia vera), and chemotherapy.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>9.</span><span style='font-size:7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;
</span><b><span style='font-size:11.0pt'>Leukostasis:</span></b><span
style='font-size:11.0pt'> occurs with very high white blood cell count in acute
leukemias.&nbsp; Symptoms include hypoxia, renal insufficiency, altered mental
status, and somnolence. Can worsen during induction chemotherapy.&nbsp; Obtain
CSF and head CT to rule out other diagnoses.&nbsp; Treat with leukopheresis,
hydration, induction chemotherapy, and possibly hydroxyurea.&nbsp; Avoid blood
product transfusions as this might worsen symptoms.&nbsp; Wait until after you
white blood cells have been removed by leukopheresis.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt'>10.</span><span style='font-size:7.0pt'>&nbsp; </span><b><span
style='font-size:11.0pt'>DIC:</span></b><span style='font-size:11.0pt'> often
occurs in patients with AML (especially M<sub>3</sub> variant) and
adenocarcinoma patients.&nbsp; Diagnose by PT/PTT, fibrinogen, platelet count,
and D-dimers.&nbsp; Treat by correcting deficits—platelet transfusions, FFP,
vitamin K, cryoprecipitate.&nbsp; Treat the underlying cause.&nbsp; Heparin is
occasionally used to suppress the consumptive process, but the data on this is
limited.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText><i><span style='font-size:9.0pt;font-family:Arial'>UCSF
Division of Hematology/Oncology Housestaff Handbook,1998.</span></i></p>

<p class=MsoFootnoteText><i><span style='font-size:9.0pt;font-family:Arial'>&nbsp;</span></i></p>

<p class=MsoFootnoteText><i><span style='font-size:9.0pt;font-family:Arial'>Brigden
ML.&nbsp; Hematologic and oncologic emergencies.&nbsp; Postgrad Med. 2001
Mar;109(3):143-6, 151-4, 157-8.</span></i></p>

<span style='font-size:10.0pt;font-family:"Times New Roman";'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoFootnoteText>&nbsp;</p>

<h1><a name="_PAIN_MANAGEMENT"></a>PAIN MANAGEMENT</h1>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>See <i><a
href="HospH2002_C13.htm#_PAIN_MANAGEMENT">Toxicology</a></i></span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText><b><span style='font-size:12.0pt;font-family:Arial'>&nbsp;</span></b></p>

<h1><a name="_COMMON_CHEMOTHERAPY_SIDE"></a>COMMON CHEMOTHERAPY SIDE EFFECTS</h1>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>For
nausea and vomiting, see <i><a href="HospH2002_C8.htm#_NAUSEA">Gastroenterology:
Nausea</a></i>.</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Anthracycline
antibiotics: cardiac toxicity in accumulated dose (consider evaluation with pretreatment
MUGA or echocardiogram).</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Cyclophosphamide:
hemorrhagic cystitis (pre-treat with mesna).</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Etoposide:
fever, hypotension during infusion, metabolic acidosis after infusion.</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Cytarabine:
severe mucositis, pink rash that can desquamate, renal insufficiency.</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Cisplatin:
renal toxicity, potassium and magnesium wasting.</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Vincristine:
peripheral neuropathy.</span></p>

<p class=MsoFootnoteText style='margin-left:.25in;text-indent:-.25in'><span
style='font-size:11.0pt;font-family:Symbol'>·</span><span style='font-size:
7.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style='font-size:11.0pt'>Bleomycin:
pulmonary fibrosis.</span></p>

<p class=MsoFootnoteText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoFootnoteText>&nbsp;</p>

</div>

</body>

</html>

</text>
